Expertise in
4
conditions

Stefania Ciolli

Florence, IT 
Expertise in
4
conditions
Florence, IT 

Overview

Stefania Ciolli practices practicing medicine in Florence, Italy.

Ms. Ciolli is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, and Small Lymphocytic Lymphoma (SLL).

She is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Florence, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia
A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Ofatumumab
Study Phase: Phase 2
A Retrospective Study to Assess the Efficacy and Safety of Chlorambucil Plus Rituximab as Front-line Therapy in Elderly and/or Unfit Patients Affected by B-cell Chronic Lymphocytic Leukemia
A Retrospective Study to Assess the Efficacy and Safety of Chlorambucil Plus Rituximab as Front-line Therapy in Elderly and/or Unfit Patients Affected by B-cell Chronic Lymphocytic Leukemia
Enrollment Status: Unknown
Publish Date: March 22, 2018
View 1 Less Clinical Trial

18 Total Publications

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Journal: American journal of hematology
Published: January 20, 2022

Frequently Asked Questions about Stefania Ciolli

Is Stefania Ciolli a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Stefania Ciolli is classified as an Distinguished expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stefania Ciolli participate in research or clinical trials?

Yes. Stefania Ciolli has published 18 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Stefania Ciolli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ciolli's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile